Suppr超能文献

PD-L1 和 B7-1 顺式相互作用:免疫检查点和免疫疗法的新机制。

PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

机构信息

Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, NY 10461, USA.

Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China.

出版信息

Trends Mol Med. 2021 Mar;27(3):207-219. doi: 10.1016/j.molmed.2020.10.004. Epub 2020 Nov 13.

Abstract

Immune checkpoints negatively regulate immune cell responses. Programmed cell death protein 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T lymphocyte-associated protein 4 (CTLA-4):B7-1 are among the most important immune checkpoint pathways, and are key targets for immunotherapies that seek to modulate the balance between stimulatory and inhibitory signals to lead to favorable therapeutic outcomes. The current dogma of these two immune checkpoint pathways has regarded them as independent with no interactions. However, the newly characterized PD-L1:B7-1 ligand-ligand cis-interaction and its ability to bind CTLA-4 and CD28, but not PD-1, suggests that these pathways have significant crosstalk. Here, we propose that the PD-L1:B7-1 cis-interaction brings novel mechanistic understanding of these pathways, new insights into mechanisms of current immunotherapies, and fresh ideas to develop better treatments in a variety of therapeutic settings.

摘要

免疫检查点负向调节免疫细胞的反应。程序性死亡蛋白 1(PD-1):程序性死亡配体 1(PD-L1)和细胞毒性 T 淋巴细胞相关蛋白 4(CTLA-4):B7-1 是最重要的免疫检查点途径之一,也是免疫疗法的关键靶点,这些疗法旨在调节刺激和抑制信号之间的平衡,从而产生有利的治疗效果。目前,关于这两条免疫检查点途径的观点一直认为它们是相互独立的,没有相互作用。然而,新发现的 PD-L1:B7-1 配体-配体顺式相互作用及其与 CTLA-4 和 CD28 结合的能力,但不能与 PD-1 结合,表明这些途径有显著的串扰。在这里,我们提出 PD-L1:B7-1 顺式相互作用为这些途径提供了新的机制理解,为当前免疫疗法的机制提供了新的见解,并为在各种治疗环境中开发更好的治疗方法提供了新的思路。

相似文献

1
PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
Trends Mol Med. 2021 Mar;27(3):207-219. doi: 10.1016/j.molmed.2020.10.004. Epub 2020 Nov 13.
2
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Immunity. 2019 Dec 17;51(6):1059-1073.e9. doi: 10.1016/j.immuni.2019.11.003. Epub 2019 Nov 19.
3
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
J Exp Clin Cancer Res. 2021 Jun 4;40(1):184. doi: 10.1186/s13046-021-01987-7.
4
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Cancer Immunol Immunother. 2005 Apr;54(4):307-14. doi: 10.1007/s00262-004-0593-x. Epub 2004 Dec 15.
5
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
Cell Mol Immunol. 2023 Jul;20(7):694-713. doi: 10.1038/s41423-023-01019-8. Epub 2023 Apr 17.
6
PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.
J Hematol Oncol. 2017 Jan 25;10(1):34. doi: 10.1186/s13045-017-0403-5.
7
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Clin Immunol. 2021 May;226:108707. doi: 10.1016/j.clim.2021.108707. Epub 2021 Mar 1.
8
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
Immunotherapy. 2019 Apr;11(5):429-441. doi: 10.2217/imt-2018-0110. Epub 2019 Jan 30.
9
A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
PLoS Comput Biol. 2021 Mar 8;17(3):e1008825. doi: 10.1371/journal.pcbi.1008825. eCollection 2021 Mar.
10
PD-L1 Binds to B7-1 Only on the Same Cell Surface.
Cancer Immunol Res. 2018 Aug;6(8):921-929. doi: 10.1158/2326-6066.CIR-17-0316. Epub 2018 Jun 5.

引用本文的文献

4
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy.
Antibodies (Basel). 2025 Apr 11;14(2):35. doi: 10.3390/antib14020035.
5
PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.
Sci Adv. 2025 Jan 31;11(5):eadt3044. doi: 10.1126/sciadv.adt3044. Epub 2025 Jan 29.
6
PD-1 immunology in the kidneys: a growing relationship.
Front Immunol. 2024 Oct 23;15:1458209. doi: 10.3389/fimmu.2024.1458209. eCollection 2024.
7
Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer.
Transl Androl Urol. 2024 Sep 30;13(9):2092-2109. doi: 10.21037/tau-24-415. Epub 2024 Sep 26.
10
zDHHC20-driven S-palmitoylation of CD80 is required for its costimulatory function.
Acta Pharmacol Sin. 2024 Jun;45(6):1214-1223. doi: 10.1038/s41401-024-01248-1. Epub 2024 Mar 11.

本文引用的文献

2
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.
Nat Cancer. 2020 Jul;1(7):681-691. doi: 10.1038/s43018-020-0075-x. Epub 2020 Jun 22.
4
Mechanistic dissection of the PD-L1:B7-1 co-inhibitory immune complex.
PLoS One. 2020 Jun 4;15(6):e0233578. doi: 10.1371/journal.pone.0233578. eCollection 2020.
5
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Sci Transl Med. 2020 Mar 11;12(534). doi: 10.1126/scitranslmed.aav7431.
6
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
Immunity. 2019 Dec 17;51(6):1059-1073.e9. doi: 10.1016/j.immuni.2019.11.003. Epub 2019 Nov 19.
7
The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.
Trends Pharmacol Sci. 2019 Nov;40(11):883-896. doi: 10.1016/j.tips.2019.09.008. Epub 2019 Oct 31.
9
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10453-10462. doi: 10.1073/pnas.1819004116. Epub 2019 May 10.
10
Abatacept modulates CD80 and CD86 expression and memory formation in human B-cells.
J Autoimmun. 2019 Jul;101:145-152. doi: 10.1016/j.jaut.2019.04.016. Epub 2019 May 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验